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Topical Peroxisome Proliferator Activated Receptor
Activators Accelerate Postnatal Stratum Corneum
Acidification
Joachim W. Fluhr1,2, Mao-Qiang Man1, Jean-Pierre Hachem1, Debra Crumrine1, Theodora M. Mauro1,3,4,
Peter M. Elias1,3,4 and Kenneth R. Feingold1,3,4
Previous studies have shown that pH declines from between 6 and 7 at birth to adult levels (pH 5.0–5.5) over 5–6
days in neonatal rat stratum corneum (SC). As a result, at birth, neonatal epidermis displays decreased
permeability barrier homeostasis and SC integrity, improving days 5–6. We determined here whether
peroxisome proliferator-activated receptor (PPAR) activators accelerate postnatal SC acidification. Topical
treatment with two different PPARa activators, clofibrate and WY14643, accelerated the postnatal decline in SC
surface pH, whereas treatment with PPARg activators did not and a PPARb/d activator had only a modest effect.
Treatment with clofibrate significantly accelerated normalization of barrier function. The morphological basis
for the improvement in barrier function in PPARa-treated animals includes accelerated secretion of lamellar
bodies and enhanced, postsecretory processing of secreted lamellar body contents into mature lamellar
membranes. Activity of b-glucocerebrosidase increased after PPARa-activator treatment. PPARa activator also
improved SC integrity, which correlated with an increase in corneodesmosome density and increased
desmoglein-1 content, with a decline in serine protease activity. Topical treatment of newborn animals with a
PPARa activator increased secretory phospholipase A2 activity, which likely accounts for accelerated SC
acidification. Thus, PPARa activators accelerate neonatal SC acidification, in parallel with improved permeability
homeostasis and SC integrity/cohesion. Hence, PPARa activators might be useful to prevent or treat certain
common neonatal dermatoses.
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INTRODUCTION
It is well known that the surface pH of the human adult skin is
acidic with a pH between 5 and 5.5 (Heuss, 1892; Schade,
1928; Marchionini and Hausknecht, 1938; Blank, 1939;
Bernstein and Hermann, 1942; Draize, 1942; Arbenz, 1952;
Behrendt and Green, 1958; Beare et al., 1960; Jolly, 1961;
Baden and Pathak, 1967; Tippelt, 1969; Braun-Falco and
Korting, 1986; Zlotogorski, 1987; Korting et al., 1990;
Seidenari and Giusti, 1995; Berardesca et al., 1998; Yosipo-
vitch et al., 1998; Eberlein-Konig et al., 2000; Fluhr et al.,
2000), but the mechanisms that account for this acidification
remain only partially defined. It has been postulated that
exogenous mechanisms (that is, originating outside the
epidermis), such as free fatty acids of pilosebaceous origin
(Puhvel et al., 1975; Bibel et al., 1989), microbial metabolites
(Di Marzio et al., 1999), and eccrine gland-derived products,
such as lactic acid (Ament et al., 1997; Thueson et al., 1998),
contribute to stratum corneum (SC) acidification. But recent
studies have shown that endogenous pathways also contribute
to SC acidification (Fluhr et al., 2001a, 2004a; Behne et al.,
2002a). Free fatty acid generation from phospholipid hydrolysis
catalyzed by secretory phospholipase A2 (sPLA2, Mao-Qiang
et al., 1996; Fluhr et al., 2001a, 2004a), generation of acidic
metabolites of filaggrin metabolism, such as cis-urocanic acid
from histidine (Schwarz et al., 1986; Krien and Kermici, 2000),
and a sodium/proton pump antiporter, sodium/hydrogen
antiporter-1 (NHE-1; Behne et al., 2002b, 2003; Fluhr et al.,
2004a), appears to contribute to SC acidification.
Yet, the skin surface is not fully acidified in newborn
rodents and humans (Behrendt and Green, 1958; Visscher
et al., 2000; Yosipovitch et al., 2000; Fluhr et al., 2004a).
While in humans it takes several weeks to months before the
SC is fully acidified (Behrendt and Green, 1958; Visscher
et al., 2000; Yosipovitch et al., 2000; Giusti et al., 2001) in
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the neonatal rat, the SC attains adult pH levels over the first
postnatal week (Fluhr et al., 2004a). Inhibition of either
sPLA2 or NHE-1 delays postnatal SC acidification, suggesting
that these two endogenous pathways of acidification con-
tribute to the postnatal acidification (Fluhr et al., 2004a) at a
time when neither the normal microbial flora nor filaggrin
proteolysis appear to be contributory. Moreover, murine
epidermis is devoid of eccrine glands, whose products
therefore are not available to acidify the SC.
While the major function of the low surface pH has been
assumed to be antimicrobial (Aly et al., 1975; Hartmann,
1983; Bibel et al., 1989), recent studies have suggested that
the acidic pH of the SC is also essential for normal
permeability barrier homeostasis and SC integrity and
cohesion (the converse of desquamation). Specifically, in
newborn rodents the recovery of permeability barrier func-
tion following acute barrier disruption is delayed because of
incomplete maturation of lamellar membranes in the SC
(Fluhr et al., 2004b), an abnormality that has been attributed
in turn to decreased activity of at least one key enzyme for
lipid processing; b-glucocerebrosidase (b-GlucCer’ase),
which exhibits optimal activity at an acidic pH. Pertinently,
both permeability barrier homeostasis and the maturation of
SC lamellar membranes improve with topical treatment of the
newborn animals with an acidic buffer (Fluhr et al., 2004b).
Similarly, abnormal SC integrity and cohesion are corrected by
topical acidic buffers (Fluhr et al., 2004b); corneodesmosomes
(CDs) density increases with acidic buffer treatment, and
desmoglein 1 (DSG1) and corneodesmosin protein content
increase in parallel. An increase in serine protease activity in
the SC in newborn animals, because of the higher pH that
optimizes catalytic activity of this family of enzymes, appears
to account for increased degradation of CD in neonatal SC.
Notably, the increased serine protease activity and the reduced
density of CD are corrected by topical treatment with an acidic
buffer linking the structural abnormalities in CD with the
alterations in SC integrity (Fluhr et al., 2004b). Together, these
experiments demonstrate that a decrease in pH in neonatal
animals improves both permeability barrier homeostasis and
SC integrity indicating an important role for pH in regulating
these functions during the perinatal period. Conversely, the
elevated surface pH in neonates could contribute to their
common clinical abnormalities.
Recent studies have shown that topical treatment of
newborn animals with activators of LXR, a nuclear hormone
receptor that forms heterodimers with RXR followed by
activation of gene transcription, can accelerate SC acidifica-
tion, at least in part because of an increase in sPLA2 activity
(Fluhr et al., 2005). This LXR-mediated acceleration of
acidification was associated with an improvement in both
permeability barrier homeostasis and SC integrity. Addition-
ally, the structural abnormalities in both SC lamellar
membranes and CD density in newborn animals were
ameliorated by treatment with LXR activators, accounting
for the improvement in these functions (Fluhr et al., 2005).
Peroxisome proliferator-activated receptors (PPARs) are
members of the same subfamily of nuclear hormone receptors
as LXR. Three isotypes have been described: PPARa (NR1C1),
PPARb/d (NR1C2), and PPARg (NR1C3), which all are
expressed in epidermis, and most specifically in human
keratinocytes (Rivier et al., 1998; Kuenzli and Saurat, 2004).
Endogenous fatty acids and their metabolites activate PPARs,
as do specific drugs (PPARa, clofibrates and WY14643;
PPARb/d, GW1514; PPARg, thiazolidinediones, such as
ciglitazone and troglitazone; Kliewer et al., 1999). In adult
animals, topical treatment with activators of these PPAR
isoforms, and the addition of activators to human keratino-
cyte cultures stimulates keratinocyte differentiation (Hanley
et al., 1998; Komuves et al., 2000; Mao-Qiang et al., 2004;
Schmuth et al., 2004). In addition, topical treatment of
normal adult animals with PPAR activators improves perme-
ability barrier homeostasis following acute barrier disruption
(Man et al., 2006). Finally, PPARa and PPARb/d activators
accelerate the formation of the epidermal permeability
barrier and stimulate differentiation during fetal develop-
ment, whereas PPARg displays no effects (Komuves et al.,
1998; Hanley et al., 1999; Michalik et al., 2002; Schmuth
et al., 2002a). Given the beneficial effect of LXR activation on
SC pH and cutaneous structure and function (Fluhr et al.,
2005), we hypothesized that treatment with one or more
PPAR activators could also accelerate neonatal acidification,
resulting in normalization of the abnormalities in cutaneous
function that occur in neonatal epidermis.
RESULTS
Topical PPARa activators accelerate postnatal acidification
Our initial experiments examined whether topical treatment
of newborn mice with PPAR activators would accelerate the
acidification of the SC. Skin surface pH varies from
approximately 6.0 to 7.0 between different litters of newborn
rats. The explanation for this variation in surface pH is
unknown but because of this variation we only compare
measurements in the same group of newborn animals studied
simultaneously under identical conditions. As shown in
Figure 1, treatment with two different PPARa activators,
clofibrate and WY14643, resulted in a decrease in SC surface
pH, whereas treatment with GW1514, a PPARb/d activator,
resulted in lesser changes than that nevertheless achieved
statistical significance. In contrast, treatment with the PPARg
activator, ciglitazone, had no effect on SC surface pH,
whereas the PPARg activator, troglitazone, actually increased
surface pH. Topical treatment with PPAR activators did not
alter either basal transepidermal water loss (TEWL) or SC
hydration (data not shown).
Accelerated postnatal acidification by PPARa activators
improves permeability barrier homeostasis in neonates
We next determined whether PPARa and PPARb/d activators,
which both accelerated postnatal acidification, would
improve permeability barrier homeostasis in neonates. As
shown in Figure 2, treatment with the PPARa activator,
clofibrate, significantly accelerated the kinetics of barrier
recovery following acute disruption by tape stripping. The
PPARb/d activator, GW1514, displayed only modest effects
on barrier recovery that did not achieve statistical signifi-
cance, consistent with the modest changes in SC pH.
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Accelerated lamellar body secretion and postsecretory lipid
processing account for improved barrier function
The morphological basis for the PPARa-activator-induced
improvement in permeability homeostasis following acute
barrier disruption is shown in electron micrographs in
Figure 3. First, accelerated secretion of lamellar bodies
occurs in clofibrate-treated animals (Figure 3c and c insert).
The increase in secretion can be readily detected at the SC:
stratum granulosum (SG) interface and within the lower
layers of the SG (premature secretion; Figure 3c). In contrast,
secretion of lamellar bodies is not observed below the SC: SG
interface in vehicle-treated or -untreated animals (Figure 3b).
The secretion of lamellar bodies below the SC: SG interface is
not usually observed (Figure 3c and c insert, arrows). Second,
there are fully processed, mature lamellar membranes within
the first and second interspace of the SC in the PPARa-
activator-treated animals (Figure 3a, arrows) whereas in
vehicle-treated control animals, the lamellar material is
largely unprocessed (Figure 3b, asterisks). b-GlucCer’ase is
a key enzyme required for processing of secreted lamellar
body lipids into mature membranes. As shown in Figure S1,
the activity of b-GlucCer’ase, measured by in situ zymo-
graphy, increases following PPARa-activator treatment of
neonatal rat skin. Together, these changes likely account for
the improvement in permeability barrier homeostasis in
PPARa-treated newborn animals.
PPARa activators improve SC integrity
The effects of topical treatment with either PPARa or PPARb/d
activator on SC integrity are shown in Figure 4. SC integrity
was assessed as the change in TEWL after three tape
strippings with D-Squame tape. The PPARa activator,
clofibrate, markedly reduced the increase in TEWL after tape
stripping indicating an improved SC integrity, whereas
GW1514, a PPARb/d activator, displayed only modest
effects, which did not achieve statistical significance. The
variation in TEWL after three tape strippings in these
experiments was similar to that seen in previous studies.
Furthermore, in the basal state there were 17–18 cell layers in
PPARa-treated neonates compared to 10–15 cell layers in
vehicle-treated neonates suggesting an increase in SC
thickness. The morphological basis for the improvement in
SC integrity with PPARa treatment is shown in Figure 5. The
density of CDs appears to increase markedly in PPARa-
treated animals in comparison to vehicle-treated neonates,
and CD persists to higher levels of SC (Figure 5a and b;
arrows). In vehicle-treated neonates, CD degradation (Figure
5c, open arrows) begins immediately above the SG–SC
interface, and few CD persist into mid-SC.
Quantitative comparison of CD density per unit length
cornified envelope (CE) in PPARa vs vehicle-treated neonates
demonstrated a more than twofold increase in CD density in
clofibrate-treated samples (Figure 6; Po0.001). Additionally,
staining for DSG1, a key protein constituent of CDs, increases
in PPARa-treated animals as shown in Figure S2. Although
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Figure 1. Topical treatment with PPARa ligand accelerates acidification of
the stratum corneum. Newborn animals were treated topically with two
PPARa activators, clofibrate and WY14643 (a, b), a PPARb/d activator
GW1514(c), and two PPARg activators, ciglitazone and troglitazone (d, e).
The compounds were dissolved in acetone at a concentration of 10mM. The
newborn rats were treated on each flank 2 per day over 3 days with 20 ml of
the freshly prepared solutions. To prevent the mothers from licking the
applied substances off the newborn rats, we placed the pups in a plastic
container in a 37 1C incubator for 2–3 hours. The pH measurements were
performed after 3 days of treatment. (N¼ 7–13; mean±SEM).
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Figure 2. Permeability barrier homeostasis is improved by topical treatment
with PPARa ligands. Treatment with the PPARa activator, clofibrate (a) and
the PPARb/d activator, GW1514 (b), was carried out as described in Figure 1.
To quantify epidermal permeability barrier function and barrier homeostasis,
we measured TEWL with an electrolytic water analyzer (MEECO). After acute
barrier disruption by tape stripping with a TEWL value of approximately
10–15 over baseline, barrier recovery rates were calculated with the
following formula: 1(TEWL immediately after strippingTEWL at different
time points)/(TEWL immediately after strippingbaseline TEWL)100%.
(N¼4–8; mean±SEM).
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the mechanism for the decrease in CD in newborn animals is
incompletely understood, in adult epidermis, CD are
degraded primarily by serine proteases in the SC (Brattsand
et al., 2005). As shown in Figure S3, serine protease activity
declines in the epidermis of neonates treated with clofibrate.
PPARa activator increases sPLA2 activity, which is important
for acidification
A number of different mechanisms could contribute to the
PPARa-induced acceleration of postnatal acidification. Pre-
vious studies have shown that sPLA2 plays an important role
in the postnatal acidification of newborn animals (Fluhr et al.,
2004a), and LXR-activator-induced postnatal acceleration of
acidification correlated with an increase in sPLA2 activity. As
shown in Figure 7, topical treatment of newborn animals with
clofibrate, a PPARa activator, increases sPLA2 activity,
whereas in contrast, immunostaining for NHE1 remains
similar in vehicle-control and clofibrate-treated newborn
animals (data not shown). Finally, that the postnatal increase
in sPLA2 activity is important for postnatal acidification is
shown in Figure 8. Simultaneous treatment with the PPARa
activator and bromphenacylbromide (BPB), a broad inhibitor
of sPLA2 activity, blocked the ability of the PPARa activator
to acidify the SC of newborn animals.
DISCUSSION
In both humans and in various animal models skin surface pH
is less acidic at birth and in humans it takes several weeks to
achieve adult levels of acidification whereas in rodents,
acidification occurs rapidly and adult levels are achieved
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Figure 3. PPARa ligands accelerate the secretion and maturation of
extracellular lamellar membranes in neonatal rat SC. The morphological
basis for the improvement in permeability homeostasis following acute barrier
disruption with PPARa activator treatment is shown in electron micrographs.
At 3 hours after barrier disruption by tape stripping, samples were obtained
and prepared for EM analysis as described in the MATERIALS and METHODS.
First, there is accelerated secretion of lamellar bodies in clofibrate-treated
animals (Figure 3c and c insert). The increase in secretion occurs both at
the SC: SG interface and in lower layers of the SG (premature secretion, c).
The secretion of lamellar bodies below the SC: SG interface is not usually
observed (c and c insert, arrows). Second, there are fully processed, mature
lamellar membranes within the first and second interspace of the SC in the
PPARa-activator-treated animals (a, arrows) whereas in vehicle (Veh)-treated
control animals, the lamellar material is largely unprocessed (b, asterisks). (a–c
and c insert), ruthenium tetroxide postfixation. Magnification bars¼0.25 mm.
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Figure 4. Topical treatment with PPARa activators normalize SC integrity.
Newborn animals were treated topically twice per day for 3 days with
clofibrate (a) or GW1514l (b). At 12 hours after the last treatment SC integrity
was assessed as the change in TEWL value after a predefined number of
D-Squame tape strippings (3 ). The increase in TEWL was markedly reduced
by treatment with the PPARa ligand. Results are presented as mean±SEM
(n¼5–6). These animals are a separate group of animals from those studied in
Figures 1 and 2. (N¼5–6).
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Figure 5. PPARa activator increases corneodesmosome density. Increased
density and persistence of corneodesmosomes (CD) in PPARa (clofibrate-
treated) neonates (a, b; arrows). In vehicle (Veh)-treated neonates, DC
degradation ((c) open arrows) begins immediately above stratum granulosum
(SG)–SC interface, and few CD persist into mid-SC. (a, b) Ruthenium tetroxide
postfixation; (c) osmium tetroxide postfixation. Magnification bars¼0.5 mm.
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within several days (Behrendt and Green, 1958; Visscher
et al., 2000; Yosipovitch et al., 2000; Fluhr et al., 2004a).
Thus, in rodents, the acidification of the SC post-birth is
compressed into a relatively short time period, which
facilitates studies. In rodents, the less acidic skin surface pH
that is present at birth results in alterations in permeability
barrier homeostasis (normal barrier function at baseline but a
delay in barrier repair after acute barrier disruption) and a
decrease in SC integrity and cohesion both of which are
corrected by acidification of the SC (Fluhr et al., 2004a, b).
The combination of decreases in both permeability barrier
homeostasis and the ability of the SC to withstand mechan-
ical injury (decreased SC integrity and cohesion) would
increase the susceptibility of the skin to cutaneous disorders.
Numerous studies and clinical observations have reported
that infants’ skin is more susceptible to injury than adult skin
(Lund et al., 1997). Moreover, it is well recognized that the
growth of skin pathogens, such as Staphylococcus aureus and
Streptococcus pyogenes, is inhibited by an acidic skin pH,
whereas the growth of normal skin flora flourishes at an
acidic pH (Puhvel et al., 1975; Korting et al., 1990, 1992).
Therefore, the increased risk of cutaneous infections in
newborns could be due in part to an elevated skin surface
pH (Yosipovitch et al., 2000) that can persist until at least 3
months (Hoeger and Enzmann, 2002), and may not become
completely normal until 2 years of age (Giusti et al., 2001).
Thus the less acidic surface pH in the newborn period could
have harmful effects. Given the potential harmful conse-
quences of a less acidic skin surface pH in newborns, we
have utilized the rodent model to begin to assess several
different therapeutic approaches to accelerate the acidifica-
tion of the SC in the newborn period. A recent study by our
laboratory has shown that topical treatment with activators of
LXR, a nuclear hormone receptor that is activated by
oxysterols, accelerates postnatal acidification of the SC (Fluhr
et al., 2005). This accelerated acidification was due in part to
an increase in sPLA2 activity. Moreover, this accelerated
acidification of the SC was associated with an improvement
in both permeability barrier homeostasis and in SC integrity/
cohesion. The improvement in barrier function was asso-
ciated with an increased maturation of lamellar membranes
attributable to an increase in the activity of b-GlucCer’ase, an
enzyme that is most active at pH 5.5. The improvement of SC
integrity/cohesion was associated with an increase in CD and
DSG1 expression (Fluhr et al., 2005).
In the present study, we explored the ability of PPAR
activators to accelerate SC acidification. There are three
PPAR isoforms, a, d, and g, and all three isoforms are present
in the epidermis (Kuenzli and Saurat, 2003). These receptors
heterodimerize with RXR and are activated by fatty acids,
prostaglandins, eicosanoids, and other lipid metabolites
(Kliewer et al., 1999). Studies by our laboratory and others
have shown that activation of PPARa, d, and g have major
effects on epidermal/keratinocyte function. First, the addition
of PPAR ligands to cultured human keratinocytes and topical
application of PPAR ligands to mouse skin stimulates the
increased expression of differentiation related proteins such
as involucrin, loricrin, profilaggrin, and transglutaminase 1
(Hanley et al., 1997; Komuves et al., 2000; Westergaard
et al., 2001; Fluhr et al., 2004a; Kuenzli and Saurat, 2004;
Mao-Qiang et al., 2004; Burdick et al., 2006). Second,
topical treatment of murine skin with PPAR ligands improves
permeability barrier homeostasis resulting in an acceleration
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Figure 6. PPARa activator clofibrate increases corneodesmosome density
significantly. Quantitation of corneodesmosome (CD) density was performed
in 25–30 randomly obtained micrographs, taken at 25,000 magnification,
using a planimeter (Plan Wheel, Scalex Corp., Carlsbad, CA), and
Scale-Link version 3.0 software (Scalex). CD density was calculated as unit
length of CD/total length of cornified envelopes (CE), and means±SEM for
each group (N¼20 clofibrate; N¼ 24 vehicle).
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Figure 7. Secretory phospholipase A2 activity is increased by topical
treatment with PPARa ligand. Newborn animals were treated topically twice
per day for 3 days with clofibrate or vehicle (control). At 12 hours after the last
treatment skin was obtained. Secretory phospholipase A2 (sPLA2) activity was
assessed in pooled, sequential SC tape strips with a fluorometric assay after
3 days of treatment. To ensure uniform removal, the D-Squame tapes were
placed on the skin surface with forceps, and the tape surface was gently
rubbed three times over its entire surface. Total sPLA2 activity in SC was
quantified as described in the MATERIALS and METHODS. The activity of
sPLA2 was calculated per cm
2 of total SC (N¼ 7–8, mean±SEM).
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Figure 8. Co-applications of BPB inhibited the SC acidification induced by
treatment with PPARa ligands. Newborn animals were treated topically
with BPB alone, clofibrate alone or both BPB and clofibrate twice a day for
3 days. On day 3, SC surface pH was measured. (N¼ 6–8; mean±SEM).
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of barrier recovery following acute disruption (Man et al.,
2006). Associated with the improved permeability barrier
homeostasis was an increase in (1) epidermal cholesterol,
fatty acid, and sphingolipid synthesis, (2) lamellar body
secretion, and (3) b-GlucCer’ase activity, all of which could
contribute to the enhanced barrier homeostasis. Finally,
PPARa and PPARd but not PPARg activators accelerate the
formation of the SC during fetal development, resulting in the
earlier appearance of a mature permeability barrier (Hanley
et al., 1997, 1999; Komuves et al., 1998; Schmuth et al.,
2002b).
We demonstrate in the present paper that topical
treatment of newborn rat skin with two different PPARa
activators accelerates the acidification of newborn SC,
whereas a PPARd activator had only a modest effect. In
contrast, treatment with a PPARg activator, ciglitazone had
no effect on SC acidification, whereas the PPARg activator,
troglitazone increased surface pH. The basis for this
difference between two different PPARg activators is un-
known but other studies have shown that the spectrum of
genes activated by different PPARg ligands can vary
considerably (Camp et al., 2000). In humans it is well
recognized that pioglitazone decreases serum triglyceride
levels in patients with diabetes whereas rosiglitazone either
has no effect or increases serum triglycerides (Goldberg et al.,
2005). In this paper, we measured surface pH but previous
studies in both adults and neonates have shown that changes
in surface pH reflect the changes in pH that occur throughout
the SC measured by fluorescence lifetime imaging (FLIM;
Behne et al., 2002a, 2003). Thus, the decrease in surface pH
reported in this paper indicates that PPAR activators are
acidifying the SC, which as discussed below will have an
impact on the catalytic activity of the enzymes that reside in
the SC. In some cases, an acidic milieu will increase enzyme
activity (for example, b-GlucCer’ase) and in other instances
will decrease catalytic activity (for example serine proteases).
Treatment with PPARa activators improved permeability
barrier homeostasis and SC integrity in newborn animals
whereas PPARd activators had only a modest effect on the
functional defects consistent with its limited effect on SC
acidification. The improvement in SC integrity/cohesion in
PPARa-activator-treated skin was associated with an increase
in the size and density of CDs and an increase in staining for
DSG1, a major protein of CDs. In adult animals, one of the
key factors regulating CD degradation is the activity of serine
proteases in the SC and we have shown that increasing the
pH in SC of adult animals increases serine protease catalytic
activity, that is, serine protease catalytic activity is inhibited
by an acidic pH and activated by a neutral pH. In previous
studies, we have shown that serine protease activity is
increased in the SC of newborn animals and can be reduced
by acidifying the SC (Fluhr et al., 2004b). In the present
paper, we demonstrate that treatment of newborn skin with
PPARa activators, which decreases SC pH, also decreases
serine protease activity and we would hypothesize that this
reduction in serine protease activity accounts, at least in part,
for the increase in CD size and density leading to an
improvement in SC integrity and cohesion.
The improvement in permeability barrier homeostasis in
the PPARa-treated newborn animals was associated with an
increase in b-GlucCer’ase activity in the SC. b-GlucCer’ase is
a key enzyme required for the extracellular conversion of
glucosylceramidase to ceramides, which allows for the
formation of mature lamellar membranes that inhibit water
movement (Holleran et al., 1993). Inhibition of b-GlucCer’-
ase activity or the absence of the enzyme in genetic disorders
(Gaucher’s disease) or knockout mice results in immature
lamellar membranes and impaired permeability barrier
homeostasis (Holleran et al., 1994). It is well known that
the activity of b-GlucCer’ase is optimal at an acidic pH and
that a neutral pH inhibits catalytic activity (Holleran et al.,
1992). Thus, the acidification of the SC induced by PPARa
activators not unexpectedly increased b-GlucCer’ase activity
thereby resulting in the appearance of more mature lamellar
membranes in the extracellular spaces of the SC. The more
mature lamellar membranes in newborn animals treated with
PPARa activators could explain the improvement in perme-
ability barrier homeostasis.
In addition to lowering SC pH, PPARa activators have
many other effects on the epidermis that could have a
beneficial effect on SC structure and function. Specifically,
previous studies in adult animals have shown that PPARa
activators improve permeability barrier homeostasis inde-
pendent of effects on SC pH by increasing epidermal lipid
synthesis, stimulating lamellar body secretion, and increasing
b-GlucCer’ase activity (Man et al., 2006) Additionally,
PPARa activators increase the expression of proteins required
for differentiation such as loricrin, involucrin, filaggrin, and
transglutaminase 1 (Hanley et al., 1999; Komuves et al.,
2000; Westergaard et al., 2001; Kuenzli and Saurat, 2003;
Schmuth et al., 2004; Burdick et al., 2006; Kim et al., 2006).
Thus, it is likely that while the decrease in SC pH induced by
PPARa activators is important in the improved function of
neonatal skin other factors are also likely to contribute to the
beneficial effects.
There are numerous potential mechanisms by which SC
pH could decrease in newborn animals. In previous studies,
we demonstrated that both NHE1 and sPLA2 play a role in SC
acidification during the neonatal period (Fluhr and Elias,
2002; Behne et al., 2003). In the present study, we
demonstrate that sPLA2 activity in the SC is increased by
topical treatment with PPARa activators during the neonatal
period. Additionally, inhibiting sPLA2 with BPB prevented
the acidification of the SC induced by PPARa activators,
further supporting a role for sPLA2. It should be recognized
that BPB has effects other than inhibiting sPLA2 activity (for
example, BPB induces calcium influx in fibroblasts (Ogata
et al., 2002) and therefore it is possible that the prevention of
SC acidification induced by PPARa activators is because of
effects other than inhibition of sPLA2 activity. In contrast,
treatment with PPARa activators did not increase staining for
NHE1, suggesting that increases in NHE1 were not account-
ing for the accelerated reduction in SC pH induced by PPARa
activators. It should be recognized that many pathways
contribute to SC acidification and it is likely that PPAR
activators could be activating multiple pathways.
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In summary, the present study demonstrates that treatment
of newborn skin with PPARa activators accelerates SC
acidification during the neonatal period. In contrast, treat-
ment with PPARg activators had no effect whereas PPARd
activators had only a modest effect. In addition, treatment
with PPARa activators also improved permeability home-
ostasis and SC integrity/cohesion in newborn animals, an
effect that could be at least partially attributed to the
acidification of the SC. It should be recognized that there
are a number of differences between rodent and human skin
and therefore further studies are required to determine if the
acceleration of stratum corneum acidification and the
beneficial effects induced by PPARa activators shown here
in newborn rodents also occurs in human newborns. These
studies suggest that PPARa activators might be of clinical
benefit in the prevention and/or treatment of cutaneous
disorders that occur during the neonatal period.
MATERIALS AND METHODS
Materials, animals, and experimental procedures
Timed-pregnant Sprague–Dawley rats were obtained from Simonson
Laboratories (Gilroy, California) and fed Purina mouse diet and
water ad libitum. The PPAR ligands were obtained as follows:
PPARa, clofibrate and WY14643 were obtained from Sigma-Aldrich
(St Louis, MO); PPARb/d, GW1514 was a gift from Dr Willson
(GlaxoSmithKline); PPARg, ciglitazone and troglitazone were
obtained from Cayman Chemical Laboratories (Ann Arbor, MI).
Animal protocols were approved by the Animal Care Subcommittee
(Veterans Affairs Medical Center, San Francisco). The compounds
were dissolved in acetone at a concentration of 10mM. The pHs of
the solutions containing PPAR activators or vehicle alone were
similar (pH 6.5–7.0). The newborn rats were treated on each flank
2 per day over 3 days with 20 ml of the freshly prepared solutions.
To prevent the mothers from licking the applied substances off the
newborn rats, we placed the pups in a plastic container in a 37 1C
incubator for 2–3 hours. The pups were placed in groups (vehicle
treated separated from activator treated). The measurements were
performed after 3 days of treatment.
Permeability barrier homeostasis. Barrier function was deter-
mined by measurement of TEWL with an electrolytic water analyzer
(MEECO, Warrington, PA). Stratum corneum hydration was mea-
sured with a corneometer (Corneometer CM 820, Courage and
Khazaka, Cologne, Germany). Surface pH was measured with a flat,
glass surface electrode from Mettler-Toledo (Giessen, Germany),
attached to a pH meter (Skin pH Meter PH 900, Courage and
Khazaka). Propylene glycol and ethanol were from Fisher Scientific
(Fairlane, NJ), whereas BPB was from Sigma Chemical Co. (St Louis,
MO). EnzCheck Protease Assay Kit was purchased from Molecular
Probes (Eugene, OR). The strippings were performed with 22mm D-
Squame 100 tapes, purchased from CuDerm (Dallas, TX). To assess
the importance of sPLA2, neonatal animals were treated topically
twice daily for 3 days with BPB (4mg/ml) in propylene glycol:etha-
nol (7:3, v/v) vehicle or the vehicle alone applied to the backs and
flanks of the newborn rats (E10 ml/cm2) as described previously for
hairless mice (Mao-Qiang et al., 1996; Fluhr et al., 2001b). The
inhibitor doses that we employed have been shown previously to
inhibit secretory PLA2 activity selectively in different tissues and cell
types (Jain et al., 1991; Hornfelt et al., 1999; Longo et al., 1999;
Okamoto et al., 2007) and to be nontoxic to murine skin, without
evidence of inhibition of other synthetic activities (Mao-Qiang et al.,
1995, 1996). Most importantly, previous studies have shown that
topical treatment with BPB inhibits the metabolism of phospholipids
to free fatty acids in the SC (Mao-Qiang et al., 1995, 1996). The
animal procedures were approved by the Animal Studies Committee
of the San Francisco Veterans Affairs Medical Center and were
performed in accordance with the guidelines.
SC integrity and barrier homeostasis. SC integrity was assessed
as the change in TEWL value after a predefined number of D-
Squame tape strippings. After acute barrier disruption by tape
stripping with a TEWL value of about 10–15 over baseline, barrier
recovery rates were calculated with the following formula:
(100(TEWL immediately after strippingTEWL at different time
points)/(TEWL immediately after strippingbaseline TEWL) 100%).
Electron microscopy
Samples for electron microscopy were minced to 1mm3 cubes,
placed in modified Karnovsky’s fixative, and postfixed in either
reduced 1% osmium or buffered 0.2% ruthenium tetroxide with
0.5% ferrocyanide (Hou et al., 1991). Samples were examined in a
Zeiss 10A electron microscope (Carl Zeiss, Thornwood, NY)
operated at 60 kV. Dr Peter Elias reviewed and interpreted the
electron micrographs without knowledge of the treatment group.
Micrographs shown for electron microscopy are representative of the
changes observed in three or more samples obtained from at least
two different litters for each treatment. Quantitation of CD density
was performed in 25–30 randomly obtained micrographs, all taken at
25,000 magnification, using a planimeter (Plan Wheel, Scalex Corp.,
Carlsbad, CA), and Scale-Link version 3.0 software (Scalex). CD
density was calculated as unit length of CD/total length of cornified
envelopes, and means±SEM for each group was compared
statistically (Figure 6).
Assessment of lipid processing enzyme activities sPLA2
activity. sPLA2 activity was assessed in pooled, sequential SC tape
strips (D-Squame) with a fluorometric assay, as described by
(Radvanyi et al., 1989; Mazereeuw-Hautier et al., 2000). Briefly,
in newborn rats, the SC was stripped down to the glistening layer
after 3 days of treatment twice daily with PPAR activators or vehicle,
and assayed as described previously (Fluhr et al., 2004b).
Zymographic assessment of b-glucocerebrosidase activity.
Enzyme activity was measured using a modification of a previously
described method (Takagi et al., 1999) that has been previously
employed in neonatal rat studies (Hachem et al., 2003; Fluhr et al.,
2004a). Briefly, enzyme activity was measured by applying 20 ml of
10mM resorufin b-D-glucopyranoside dissolved in dimethyl sulfoxide
to the backs of the newborn rats. The resorufin dye becomes
fluorescent once the substrate is enzymatically cleaved. Following
topical application, neonatal pups were placed for 2–3 hours in a
plastic container at 37–38 1C. At the end of these in vivo incubations,
4-mm punch-out biopsies were taken from treated and control sites.
The biopsies were placed on a plastic coverslip with a punched out
center, inverted onto a microscopic slide, and covered with a
second, nonpunched coverslip. The cleaved compound was
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visualized with a confocal microscope at an excitation wavelength
of 568 nm and an emission wavelength of 580 nm. Resorufin alone
served as an additional negative control and as a further check for
specificity (data not shown). b-GlucCer’ase enzyme activity was
blocked when the fluorogenic substrate was co-applied with 10mM
conduritol B epoxide (data not shown).
Zymographic assessment of protease activity. Enzyme activity
was assessed as previously described (Hachem et al., 2003; Fluhr
et al., 2004a) with skin from treated neonatal rats. To obtain en face
views harvested skin was placed in a chamber slide system with the
SC facing toward the beam and visualized directly in a confocal
microscope (Leica TCS SP, Heidelberg, Germany) at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm.
Immunofluorescence
Desmoglein 1 expression. DSG 1 expression was visualized as
described previously (Fluhr et al., 2001a).
NHE1 expression. Rabbit anti-mouse NHE1 antibody was
purchased from Chemicom (Temecula, CA) and FITC-labeled goat
anti-rabbit antibody was purchased from Jackson Immunoresearch
Laboratories, INC (West Grove, PA). Skin biopsies were taken after 3
days of vehicle or activator treatment. sections (10 mm) were
incubated with NHE1 antibody at a concentration of 15mg/ml for
2 hours at room temperature. After washing three times with PBS a
1:200 dilution of FITC-labeled secondary was applied to sections
and incubated for 30minutes at room temperature.
Statistical analyses
Statistical analyses were performed using Prism 3 (GraphPad
Software Inc., San Diego, CA). Normal distribution was tested
before calculating the comparison with an unpaired t-test. In
experiments with more than three groups, an analysis of variance
was calculated followed by an a-corrected post hoc test (Bonferroni).
Values are expressed as mean±SEM. The significance level was set
at Po0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. The activity of b-glucocerebrosidase in neonatal rat stratum
corneum is increased by treatment with PPARa ligands.
Figure S2. Desmoglein 1 Expression is increased by topical treatment with
PPARa ligands.
Figure S3. Protease activity is decreased by PPARa ligands.
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